{"filing":{"accession_number":"0001193125-26-341293","cik":"0001479615","ticker":"SLNCF","company_name":"Silence Therapeutics plc","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"d12947d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526341293/d12947d8k.htm"},"events":[{"id":26381,"run_id":23972,"accession_number":"0001193125-26-341293","anchor_item_number":"7.01","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Silence Therapeutics announced positive Phase 2 SANRECO trial results for divesiran in polycythemia vera on August 10, 2026, meeting primary and secondary endpoints with strong efficacy and safety profiles. The disclosure includes trial outcomes, safety findings, and plans for Phase 3 initiation, representing a material clinical milestone for the clinical-stage biotech company.","company_name":"Silence Therapeutics plc","ticker":"SLNCF","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27477,"accession_number":"0001193125-26-341293","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses positive topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera, announced via press release on August 10, 2026. While this is clinical trial data rather than financial earnings, it represents a material clinical milestone disclosure that would significantly affect investor assessment of the company's pipeline and prospects. The disclosure includes trial outcomes, efficacy data, safety findings, and plans for Phase 3 initiation—information typically conveyed through earnings-release-style announcements in biotech companies. The Item 7.01 Regulation FD Disclosure format and attached press release (Exhibit 99.1) are consistent with how clinical-stage biotech companies announce material clinical results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:58:44.465855+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27478,"accession_number":"0001193125-26-341293","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces positive Phase 2 trial results for divesiran in polycythemia vera, meeting primary and secondary endpoints with strong efficacy and safety profiles. This is a material clinical milestone for a clinical-stage biotech company that would affect investor assessment of the registrant's pipeline progress and regulatory pathway. While not a traditional earnings release (which reports financial results), this operational/clinical milestone is material to the company's value proposition and future prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:58:44.465855+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27477,"accession_number":"0001193125-26-341293","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses positive topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera, announced via press release on August 10, 2026. While this is clinical trial data rather than financial earnings, it represents a material clinical milestone disclosure that would significantly affect investor assessment of the company's pipeline and prospects. The disclosure includes trial outcomes, efficacy data, safety findings, and plans for Phase 3 initiation—information typically conveyed through earnings-release-style announcements in biotech companies. The Item 7.01 Regulation FD Disclosure format and attached press release (Exhibit 99.1) are consistent with how clinical-stage biotech companies announce material clinical results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:58:44.465855+00:00","company_name":"Silence Therapeutics plc","ticker":"SLNCF","filing_date":"2026-08-10"},{"id":27478,"accession_number":"0001193125-26-341293","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces positive Phase 2 trial results for divesiran in polycythemia vera, meeting primary and secondary endpoints with strong efficacy and safety profiles. This is a material clinical milestone for a clinical-stage biotech company that would affect investor assessment of the registrant's pipeline progress and regulatory pathway. While not a traditional earnings release (which reports financial results), this operational/clinical milestone is material to the company's value proposition and future prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:58:44.465855+00:00","company_name":"Silence Therapeutics plc","ticker":"SLNCF","filing_date":"2026-08-10"}]}